info@cytomedix.com
Investor Relations
|
Press Releases
|
SEC Filings
|
Stock Info
|
Corporate Governance
|
Investor Communications
2008 Press Releases for
GTF
(NYSE)
2008
Dec 10
Cytomedix Announces Publication of Economic Model Indicating Cost-Effectiveness of AutoloGel™ for Diabetic Foot Ulcers
2008
Oct 20
Cytomedix To Present At Rodman & Renshaw 10
TH
Annual Healthcare Conference On Wednesday, Nov. 12, 2008
2008
Sep 19
Cytomedix On Track With Sales and Marketing Efforts For AutoloGel™ System and Further Development of CT-112 Peptide, Annual Meeting Told
2008
Sep 10
Cytomedix Appoints Dr. Peter A. Clausen as Vice President of Business Development
2008
Sep 08
Cytomedix Completes $1.5 Million Capital Raise
2008
Aug 19
Cytomedix CEO Martin Rosendale Discusses Company in Interview with the Wall Street Transcript
The Wall Street Transcript - August 18, 2008
2008
Jul 28
Cytomedix Retains Dr. David F. Counts, Inventor of Company's Anti-Inflammatory Peptide Patent
2008
Jul 16
Cytomedix CEO Issues Shareholder Update
2008
Jun 12
Cytomedix Unveils Clinical Plans for the Development of Anti-Inflammatory Peptides
2008
Jun 09
Cytomedix Announces Transition of Leadership Martin Rosendale Appointed CEO
2008
May 14
Cytomedix Joins The Acute Long Term Hospital Association (ALTHA) as an Allied Member
2008
May 05
Cytomedix Gains Access To U.S. Government Medical Facilities By Adding The AutoloGel™ System To The Federal Supply Schedule
2008
Apr 22
Cytomedix Provides Update on Efforts to Secure Medicare Reimbursement for Its AutoloGel™ System
2008
Apr 10
Cytomedix to Exhibit at the 21ST Annaul Symposium On Advanced Wound Care (SAWC) April 24-27, 2008
2008
Mar 19
Centers For Medicare And Medicaid Services (CMS) Reaches Final Coverage Decision on PRP GEL
2008
Mar 17
Cytomedix Appoints Martin P. Rosendale Executive Vice President and Chief Operating Officer
2008
Feb 12
The Kon-Lin Letter Initiates New Coverage of Cytomedix In Its February 2008 Issue With Initial Target of $4.50-$5.00 and Ultimate Target of $7-$9
2008
Jan 30
Cytomedix Submits Comments in Response to CMS’ Proposed National Coverage Decision
©
2009 Cytomedix. All Rights Reserved.
Site Map
| Terms & Conditions